EP Patent

EP2298321A1 — Novel pharmaceutical compositions for treating IBD

Assigned to NORDIC PHARMA · Expires 2011-03-23 · 15y expired

What this patent protects

A stable and/or synergistic pharmaceutical composition comprising: a) prednisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rect…

USPTO Abstract

A stable and/or synergistic pharmaceutical composition comprising: a) prednisolone metasulfobenzoate (PMSB) or its acceptable salts, preferably prednisolone metasulfobenzoate sodium and b) 5-ASA, derivatives or pharmaceutically acceptable salts thereof, which is suitable for rectal administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2298321A1
Jurisdiction
EP
Classification
—
Expires
2011-03-23
Drug substance claim
No
Drug product claim
No
Assignee
NORDIC PHARMA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.